Avenue Therapeutics announced that all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy, SBMA, also known as Kennedy’s Disease. AJ201 is currently the lead drug candidate in the clinic for SBMA, and topline data are anticipated in the second quarter of 2024. “We are pleased with the speed of enrollment in our Phase 1b/2a study evaluating AJ201 for the treatment of SBMA, reflecting the large unmet need in this debilitating neurodegenerative disease,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. “We are intently focused on advancing this much needed drug for patients and their caregivers, and we look forward to reporting topline data in the second quarter of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ATXI:
- Avenue Therapeutics initiated yesterday with a Buy at Maxim
- Avenue Therapeutics initiated with bullish view at Maxim
- Avenue Therapeutics to present preclinical in vivo data on BAER-101
- Avenue Therapeutics reports Q3 EPS 6c vs (45c) last year
- Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
